Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 9/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31676346 | 0.89 | SYK (0.49) | SYKIRAK4HTR2ASLC6A4ADRB2 | |
| SCHEMBL30613585 | 0.86 | SYK (0.49) | SYKIRAK4HTR2ASLC6A4ADRB2 | |
| SCHEMBL31676198 | 0.86 | SYK (0.47) | SYKIRAK4HTR2ASLC6A4ADRB2 | |
| SCHEMBL31676131 | 0.85 | SYK (0.43) | SYK | |
| SCHEMBL31676093 | 0.84 | IRAK4 (0.47) | SYKIRAK4HTR2ASLC6A4ADRB2 | |
| SCHEMBL31676185 | 0.84 | SYK (0.46) | SYK | |
| SCHEMBL31676186 | 0.83 | SYK (0.47) | SYKIRAK4HTR2ASLC6A4ADRB2 | |
| SCHEMBL31676259 | 0.82 | SYK (0.45) | SYKIRAK4HTR2ASLC6A4ADRB2 | |
| SCHEMBL31676203 | 0.82 | SYK (0.44) | SYKIRAK4HTR2ASLC6A4ADRB2 | |
| SCHEMBL31676110 | 0.82 | SYK (0.44) | SYKIRAK4HTR2ASLC6A4ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | UNIQUEST PTY LTD (AU) | 2025-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | LCK, BTK, SYK | SYK 3/4885IRAK4 156/4885HTR2A 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.